Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.3448 -0.0252 (-6.81%)
Streaming Delayed Price Updated: 3:36 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 Next >
News headline image
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
News headline image
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
News headline image
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
News headline image
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Reports 2023 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.